BRPI0909040A2 - - Google Patents
Info
- Publication number
- BRPI0909040A2 BRPI0909040A2 BRPI0909040A BRPI0909040A2 BR PI0909040 A2 BRPI0909040 A2 BR PI0909040A2 BR PI0909040 A BRPI0909040 A BR PI0909040A BR PI0909040 A2 BRPI0909040 A2 BR PI0909040A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60Q—ARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
- B60Q3/00—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors
- B60Q3/70—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors characterised by the purpose
- B60Q3/76—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors characterised by the purpose for spotlighting, e.g. reading lamps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60Q—ARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
- B60Q3/00—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors
- B60Q3/80—Circuits; Control arrangements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S362/00—Illumination
- Y10S362/80—Light emitting diode
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S362/00—Illumination
- Y10S362/802—Position or condition responsive switch
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3566208P | 2008-03-11 | 2008-03-11 | |
| US14498209P | 2009-01-15 | 2009-01-15 | |
| PCT/US2009/036635 WO2009114512A1 (en) | 2008-03-11 | 2009-03-10 | Azetidine and cyclobutane derivatives as jak inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0909040A2 true BRPI0909040A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2017-09-19 |
| BRPI0909040A8 BRPI0909040A8 (pt) | 2017-12-12 |
| BRPI0909040B1 BRPI0909040B1 (pt) | 2019-10-22 |
| BRPI0909040B8 BRPI0909040B8 (pt) | 2021-05-25 |
Family
ID=40591836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909040A BRPI0909040B8 (pt) | 2008-03-11 | 2009-03-10 | derivados de azetidina e ciclobutano, seus usos, e composição |
Country Status (43)
Families Citing this family (303)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| LT2426129T (lt) | 2005-12-13 | 2017-02-10 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
| US8513270B2 (en) * | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| PL2173752T5 (pl) | 2007-06-13 | 2022-12-05 | Incyte Holdings Corporation | Sole (r)-3-(4-(7h-pirolo(2,3-d)pirymidyn-4-ylo)-1h-pirazol-1-ilo)-3-cyklopentylopropanonitrylu inhibitora kinazy janusowej |
| EA020777B1 (ru) * | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| CN104387382A (zh) | 2008-03-24 | 2015-03-04 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
| US20100048557A1 (en) * | 2008-06-20 | 2010-02-25 | Bing-Yan Zhu | Triazolopyridine JAK Inhibitor Compounds and Methods |
| PE20110063A1 (es) * | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| TW201100429A (en) * | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| KR20180126619A (ko) * | 2009-10-09 | 2018-11-27 | 인사이트 홀딩스 코포레이션 | 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
| JP5858434B2 (ja) * | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
| AU2015205858B2 (en) * | 2010-03-10 | 2017-04-13 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EP2545045B1 (en) * | 2010-03-10 | 2016-01-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EP2558468B1 (en) | 2010-04-14 | 2015-04-01 | Array Biopharma, Inc. | 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases |
| DK2574168T3 (en) | 2010-05-21 | 2016-05-09 | Incyte Holdings Corp | Topical formulation to a jak inhibitor |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| ES2541289T3 (es) * | 2010-12-01 | 2015-07-17 | Nissan Chemical Industries, Ltd. | Compuestos de pirazol que tienen un efecto terapéutico sobre mieloma múltiple |
| MX357939B (es) | 2011-02-18 | 2018-07-31 | Novartis Pharma Ag | Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak). |
| CN103476416B (zh) | 2011-02-18 | 2016-09-21 | 梅迪维新技术公司 | 治疗高血压的化合物和方法 |
| RU2596829C2 (ru) * | 2011-03-08 | 2016-09-10 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Получение производного 1-амино-3-гидроксициклобутан-1-карбоновой кислоты |
| MY165963A (en) * | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AU2012313094B2 (en) * | 2011-09-22 | 2017-02-02 | Intervet International B.V. | Pyrazole carboxamides as janus kinase inhibitors |
| US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| KR20150034209A (ko) | 2012-06-26 | 2015-04-02 | 델 마 파마슈티컬스 인코포레이티드 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| US9688661B2 (en) * | 2012-08-02 | 2017-06-27 | Nerviano Medical Sciences S.R.L. | Substituted pyrroles active as kinases inhibitors |
| MX361499B (es) * | 2012-08-17 | 2018-12-06 | Concert Pharmaceuticals Inc | Baricitinib deuterado. |
| PE20151141A1 (es) | 2012-11-01 | 2015-08-06 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de jak |
| SG10202111768XA (en) | 2012-11-15 | 2021-11-29 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
| RS58547B1 (sr) | 2013-03-06 | 2019-05-31 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| SI3786162T1 (sl) | 2013-05-17 | 2024-02-29 | Incyte Holdings Corporation | Bipirazolni derivati kot zaviralci JAK |
| US9974774B2 (en) | 2013-07-26 | 2018-05-22 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
| PE20220579A1 (es) * | 2013-08-07 | 2022-04-20 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 |
| EP3035966A1 (en) | 2013-08-20 | 2016-06-29 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| UA126541C2 (uk) | 2014-02-13 | 2022-11-02 | Інсайт Холдинґс Корпорейшн | Циклопропіламіни як інгібітори lsd1 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| KR102352408B1 (ko) | 2014-02-13 | 2022-01-18 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| ES2688553T3 (es) | 2014-02-28 | 2018-11-05 | Incyte Corporation | Inhibidores de JAK1 para el tratamiento de síndromes mielodisplásicos |
| WO2015145286A1 (en) * | 2014-03-28 | 2015-10-01 | Sun Pharmaceutical Industries Limited | Amorphous form of baricitinib |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| US9938283B2 (en) | 2014-05-01 | 2018-04-10 | Sun Pharmaceutical Industries Limited | Crystalline form of baricitinib |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| US20170239351A1 (en) | 2014-08-11 | 2017-08-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
| US11311512B2 (en) | 2014-08-12 | 2022-04-26 | Monash University | Lymph directing prodrugs |
| TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| CN105524067A (zh) * | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
| EP3215518B1 (en) | 2014-10-29 | 2021-02-24 | BicycleRD Limited | Bicyclic peptide ligands specific for mt1-mmp |
| US9873706B2 (en) | 2014-12-05 | 2018-01-23 | Sun Pharmaceutical Industries Limited | Process for the preparation of baricitinib and an intermediate thereof |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| WO2016125080A2 (en) * | 2015-02-02 | 2016-08-11 | Sun Pharmaceutical Industries Limited | Process for the preparation of baricitinib and an intermediate thereof |
| EP3253760A4 (en) * | 2015-02-02 | 2018-06-20 | Sun Pharmaceutical Industries Limited | Process for the preparation of baricitinib and an intermediate thereof |
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN105924444B (zh) * | 2015-03-11 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | Jak抑制剂的晶型及其制备方法 |
| US10377757B2 (en) | 2015-03-11 | 2019-08-13 | Crystal Pharmatech Co., Ltd. | Crystal form of JAK inhibitor and preparation method thereof |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| AR104918A1 (es) | 2015-06-19 | 2017-08-23 | Lilly Co Eli | Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| AU2016306555B2 (en) | 2015-08-12 | 2021-01-28 | Incyte Holdings Corporation | Salts of an LSD1 inhibitor |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| CN118063537A (zh) | 2015-09-08 | 2024-05-24 | 莫纳什大学 | 定向淋巴的前药 |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN106554363B (zh) * | 2015-09-28 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 一种Baricitinib中间体的制备方法 |
| BR122021005850B1 (pt) | 2015-10-23 | 2023-12-26 | Navitor Pharmaceuticals, Inc | Compostos, composições moduladoras da interação sestrina-gator2 e usos destes |
| RU2603959C1 (ru) * | 2015-11-13 | 2016-12-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| ES2830446T3 (es) * | 2015-12-11 | 2021-06-03 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Derivado de azetidina, método de preparación del mismo y uso del mismo |
| US11370792B2 (en) | 2015-12-14 | 2022-06-28 | Raze Therapeutics, Inc. | Caffeine inhibitors of MTHFD2 and uses thereof |
| HU230805B1 (hu) * | 2015-12-23 | 2018-06-28 | Egis Gyógyszergyár Zrt | Eljárás és köztitermék baricitinib előállítására |
| HU230931B1 (hu) * | 2016-01-21 | 2019-04-29 | Egis Gyógyszergyár Zrt. | Baricitinib sók |
| EP3409673B1 (en) * | 2016-01-26 | 2021-06-16 | Hangzhou Bangshun Pharmaceutical Co., Ltd. | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
| CN105566332B (zh) * | 2016-01-29 | 2018-01-16 | 上海宣创生物科技有限公司 | 巴瑞克替尼三氟乙酸盐a晶型和b晶型及其制备方法 |
| CN105601635B (zh) * | 2016-02-01 | 2017-12-12 | 上海宣创生物科技有限公司 | 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法 |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| PL3426244T3 (pl) | 2016-03-09 | 2023-09-25 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
| HRP20211220T1 (hr) | 2016-03-09 | 2021-10-29 | Raze Therapeutics Inc. | Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba |
| CN107200742A (zh) * | 2016-03-18 | 2017-09-26 | 罗欣生物科技（上海）有限公司 | 一种巴瑞克替尼磷酸盐晶体及其制备方法 |
| CN107226814A (zh) * | 2016-03-23 | 2017-10-03 | 罗欣生物科技（上海）有限公司 | 一种巴瑞克替尼中间体的制备方法 |
| EP3440112A4 (en) | 2016-04-08 | 2019-10-09 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| SG11201809299QA (en) | 2016-04-22 | 2018-11-29 | Incyte Corp | Formulations of an lsd1 inhibitor |
| CN107334738B (zh) * | 2016-04-28 | 2021-02-09 | 天津科伦药物研究有限公司 | 一种含巴瑞克替尼的药物组合物及其制备方法和用途 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| JP6978098B2 (ja) * | 2016-07-26 | 2021-12-08 | スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. | 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用 |
| CN106496233B (zh) * | 2016-09-26 | 2018-05-15 | 东南大学 | 吡咯并嘧啶类化合物、其制备方法及其用途 |
| CN115448916A (zh) | 2016-10-14 | 2022-12-09 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP3538091A4 (en) | 2016-11-08 | 2020-06-10 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF |
| CZ2016705A3 (cs) | 2016-11-11 | 2018-05-23 | Zentiva, K.S. | Krystalické formy 2- [1-ethylsulfonyl-3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) pyrazol-1-yl] azetidin-3-yl] acetonitrilových solí a jejich příprava |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| EP3327020A1 (en) | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| WO2018106636A1 (en) | 2016-12-05 | 2018-06-14 | Raze Therapeutics, Inc. | Shmt inhibitors and uses thereof |
| RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
| CZ2016816A3 (cs) | 2016-12-21 | 2018-07-04 | Zentiva, K.S. | Krystalické formy 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrilu s kyselinou fosforečnou a způsob jejich přípravy |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
| EA039344B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение |
| JP7112755B2 (ja) * | 2017-01-23 | 2022-08-04 | シャンハイ ロングウッド バイオファーマシューティカルズ カンパニー リミテッド | Ｊａｋ酵素阻害剤及びその製造方法と用途 |
| AR111233A1 (es) | 2017-03-08 | 2019-06-19 | Nimbus Lakshmi Inc | Inhibidores de tyk2, usos y métodos para la producción de los mismos |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| CN106946917B (zh) * | 2017-03-20 | 2019-06-11 | 杭州科巢生物科技有限公司 | 一种jak抑制剂巴瑞替尼及其中间体的新合成方法 |
| CN107176955B (zh) * | 2017-03-24 | 2019-04-09 | 南京优科制药有限公司 | 一种巴瑞替尼的制备方法 |
| US11339144B2 (en) | 2017-04-10 | 2022-05-24 | Navitor Pharmaceuticals, Inc. | Heteroaryl Rheb inhibitors and uses thereof |
| US10912750B2 (en) | 2017-04-26 | 2021-02-09 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| BR112019024509A2 (pt) | 2017-05-23 | 2020-06-23 | Theravance Biopharma R&D Ip, Llc | Glicuronídeo de pró-fármacos dos inibidores da janus quinase |
| ES2937823T3 (es) * | 2017-06-07 | 2023-03-31 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Forma sólida del derivado de azetidina y método de preparación del mismo y uso del mismo |
| CN110799512A (zh) * | 2017-06-22 | 2020-02-14 | 苏州科睿思制药有限公司 | 巴瑞克替尼的晶型及其制备方法 |
| CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
| WO2019003249A1 (en) | 2017-06-28 | 2019-01-03 | Mylan Laboratories Limited | POLYMORPHIC FORMS OF BARICITINIB |
| SG11202000714QA (en) | 2017-07-28 | 2020-02-27 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| WO2019046491A1 (en) | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| CN109651424B (zh) * | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| IL295978B2 (en) | 2017-10-18 | 2024-01-01 | Incyte Corp | Concentrated imidazole derivatives substituted by tertiary hydroxy groups as P13K-gamma inhibitors |
| US10981906B2 (en) * | 2017-11-03 | 2021-04-20 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same |
| CN113149993A (zh) * | 2017-12-01 | 2021-07-23 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN108129482A (zh) * | 2017-12-13 | 2018-06-08 | 江苏中邦制药有限公司 | 一种巴瑞替尼的制备方法 |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| EP3727362A4 (en) | 2017-12-19 | 2021-10-06 | PureTech LYT, Inc. | MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| EP3502114A1 (en) | 2017-12-20 | 2019-06-26 | Sandoz AG | Co-crystal of an orally available janus kinase inhibitor |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| IL276147B2 (en) | 2018-01-29 | 2024-10-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| SG11202006701TA (en) | 2018-01-29 | 2020-08-28 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| CN118490690A (zh) | 2018-02-16 | 2024-08-16 | 因赛特公司 | 用于治疗细胞因子相关的病症的jak1通路抑制剂 |
| EP3755725A1 (en) | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
| KR20200140262A (ko) | 2018-02-27 | 2020-12-15 | 아텍스 바이오파마 인코포레이티드 | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 |
| CN110357887B (zh) * | 2018-03-26 | 2022-09-16 | 武汉誉祥医药科技有限公司 | 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
| IL277538B2 (en) | 2018-03-30 | 2024-09-01 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
| US11372003B2 (en) | 2018-04-13 | 2022-06-28 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| SMT202200308T1 (it) | 2018-04-24 | 2022-09-14 | Vertex Pharma | Composti antiproliferazione e loro usi |
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
| CN108752254B (zh) * | 2018-05-22 | 2021-11-02 | 道合(潍坊)医药技术有限公司 | 2-[1-(乙基磺酰基)-3-氮杂环丁亚基]乙腈的制备方法 |
| WO2019224803A2 (en) * | 2018-05-25 | 2019-11-28 | Kartos Therapeutics, Inc. | Methods of treating myeloproliferative neoplasms |
| WO2019233434A1 (zh) * | 2018-06-06 | 2019-12-12 | 杭州澳津生物医药技术有限公司 | 一种吡唑嘧啶衍生物及其用途和药物组合物 |
| IL314362A (en) | 2018-06-15 | 2024-09-01 | Janssen Pharmaceutica Nv | Rapamycin analogs and their uses |
| IL279489B1 (en) | 2018-06-22 | 2025-06-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate comprising the peptide ligand and a pharmaceutical composition comprising the drug conjugate |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN109215136B (zh) | 2018-09-07 | 2020-03-20 | 百度在线网络技术（北京）有限公司 | 一种真实数据增强方法、装置以及终端 |
| WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
| CN109146898B (zh) | 2018-09-07 | 2020-07-24 | 百度在线网络技术（北京）有限公司 | 一种仿真数据量增强方法、装置以及终端 |
| WO2020072870A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Co-crystal forms of baricitinib |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| TW202033198A (zh) | 2018-10-17 | 2020-09-16 | 美商美國禮來大藥廠 | 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎 |
| JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
| JP7644002B2 (ja) | 2018-10-24 | 2025-03-11 | ナビター ファーマシューティカルズ， インコーポレイテッド | 多形化合物およびその使用 |
| MX2021004946A (es) | 2018-10-31 | 2021-07-15 | Incyte Corp | Terapia combinada para tratamiento de enfermedades hematológicas. |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| EP3886843A4 (en) | 2018-11-30 | 2022-08-31 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| KR20210107069A (ko) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
| AU2020212001A1 (en) | 2019-01-23 | 2021-07-22 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| BR112021014525A8 (pt) * | 2019-01-30 | 2022-11-22 | Gargamel Zhuhai Biotech Ltd | Inibidor de jak e método de preparação do mesmo |
| WO2020163431A1 (en) | 2019-02-05 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Crystalline solid forms of baricitinib |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| WO2020173364A1 (zh) * | 2019-02-27 | 2020-09-03 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
| US12398141B2 (en) | 2019-03-14 | 2025-08-26 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AU2020253990A1 (en) | 2019-04-02 | 2021-10-28 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| CN113939300A (zh) | 2019-04-05 | 2022-01-14 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| EP3725305A1 (en) | 2019-04-17 | 2020-10-21 | Zentiva K.S. | Pharmaceutical composition containing baricitinib hydrobromide |
| WO2020219524A1 (en) * | 2019-04-24 | 2020-10-29 | Elanco Us Inc. | A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN110256441A (zh) * | 2019-06-24 | 2019-09-20 | 江苏君若医药有限公司 | 一种巴瑞克替尼的制备方法 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| EP3771715A1 (en) | 2019-08-02 | 2021-02-03 | Zaklady Farmaceutyczne "Polpharma" S.A. | Crystalline forms of baricitinib |
| EP3771716A1 (en) | 2019-08-02 | 2021-02-03 | Zaklady Farmaceutyczne "Polpharma" S.A. | Low hygroscopic amorphous form of baricitinib |
| JP2022548594A (ja) | 2019-09-11 | 2022-11-21 | ビンシア・バイオサイエンシーズ・インコーポレイテッド | Ｕｓｐ３０阻害剤及びその使用 |
| CN114945366B (zh) | 2019-09-13 | 2025-01-07 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| CA3157499A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CN110683978A (zh) * | 2019-10-30 | 2020-01-14 | 西安医学院 | 一种3-腈基亚甲基氮杂环丁烷-1-碳酸叔丁酯的制备方法 |
| AU2020376950A1 (en) | 2019-11-01 | 2022-06-09 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CR20220280A (es) | 2019-11-22 | 2022-09-02 | Incyte Corp | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 |
| PH12022551359A1 (en) * | 2019-12-04 | 2023-11-20 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | Rapamycin analogs and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| EP4076649A1 (en) | 2019-12-19 | 2022-10-26 | Liminal Biosciences Limited | Cycloalkyl-containing carboxylic acids and uses thereof |
| KR20220151160A (ko) | 2019-12-23 | 2022-11-14 | 카이메라 쎄라퓨틱스 인코포레이티드 | Smarca 분해제 및 이의 용도 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021159021A1 (en) | 2020-02-05 | 2021-08-12 | Puretech Lyt, Inc. | Lipid prodrugs of neurosteroids |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| CN115776887A (zh) | 2020-03-19 | 2023-03-10 | 凯麦拉医疗公司 | Mdm2降解剂和其用途 |
| CN113443986A (zh) * | 2020-03-27 | 2021-09-28 | 南京药石科技股份有限公司 | 一种合成3-氧代-1-环丁烷羧酸的中间体的制备方法 |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN111362853A (zh) * | 2020-04-27 | 2020-07-03 | 安徽大学 | 一种3-氧杂氮杂环丁烷-1-羧酸叔丁酯的制备方法 |
| CN113582901A (zh) * | 2020-05-01 | 2021-11-02 | 浙江瑞博制药有限公司 | 一种氧化反应氧化醇制备醛或酮的方法 |
| BR112022022986A2 (pt) | 2020-05-13 | 2023-01-17 | Disc Medicine Inc | Anticorpos anti-hemojuvelina (hjv) para tratar mielofibrose |
| MA59824B1 (fr) | 2020-06-02 | 2024-11-29 | Incyte Corporation | Procédés de préparation d'un inhibiteur de jak1 |
| US20230250110A1 (en) | 2020-06-03 | 2023-08-10 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| SI4175719T1 (sl) | 2020-07-02 | 2025-07-31 | Incyte Corporation | Triciklične sečninske spojine kot zaviralci jak2 v617f |
| CN111999400B (zh) * | 2020-07-15 | 2022-07-01 | 安徽联创生物医药股份有限公司 | 一种用hplc分离测定巴瑞替尼原料药杂质的方法 |
| CN111848491B (zh) * | 2020-08-10 | 2022-06-17 | 烟台大学 | 1-甲酰基咔唑的制备方法 |
| CN111875534B (zh) * | 2020-08-10 | 2022-06-17 | 烟台大学 | 1,8-二甲酰基咔唑的安全高效制备方法 |
| AU2021327130A1 (en) | 2020-08-17 | 2023-03-02 | Bicycletx Limited | Bicycle conjugates specific for Nectin-4 and uses thereof |
| CR20230130A (es) | 2020-08-18 | 2023-07-13 | Incyte Corp | Proceso e intermedios para preparar un inhibidor de jak1 |
| AU2021329303A1 (en) | 2020-08-18 | 2023-04-06 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| TW202233612A (zh) | 2020-10-23 | 2022-09-01 | 美商林伯士科羅索公司 | Ctps1抑制劑及其用途 |
| US20230404925A1 (en) | 2020-10-23 | 2023-12-21 | Elanco Us Inc. | Jak inhibitors having a specific particle size distribution |
| CN114437079B (zh) * | 2020-10-30 | 2024-11-01 | 杭州邦顺制药有限公司 | 吡咯嘧啶五元氮杂环化合物的晶型 |
| CN117015531A (zh) | 2020-12-02 | 2023-11-07 | 医肯纳肿瘤学公司 | Tead抑制剂及其用途 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202237089A (zh) | 2020-12-08 | 2022-10-01 | 美商英塞特公司 | 用於治療白斑病之ｊａｋ１途徑抑制劑 |
| CA3201608A1 (en) | 2020-12-18 | 2022-06-23 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| JP2024503300A (ja) | 2020-12-30 | 2024-01-25 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN116888116A (zh) | 2021-02-02 | 2023-10-13 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| EP4288427A1 (en) | 2021-02-02 | 2023-12-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN114907354B (zh) * | 2021-02-07 | 2024-04-09 | 南京知和医药科技有限公司 | 一种磺酰胺类多环化合物及其制备方法与用途 |
| CN114907353A (zh) * | 2021-02-09 | 2022-08-16 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| IL304907A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | Irak4 degraders and uses thereof |
| US11773103B2 (en) | 2021-02-15 | 2023-10-03 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| JP2024507935A (ja) | 2021-02-25 | 2024-02-21 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としてのスピロ環式ラクタム |
| CN114957260B (zh) * | 2021-02-26 | 2024-04-09 | 南京知和医药科技有限公司 | 一种巴瑞替尼衍生物及其制备方法与用途 |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| IL307479A (en) | 2021-04-09 | 2023-12-01 | Nimbus Clio Inc | Cbl-b modulators and uses thereof |
| IL307673A (en) | 2021-04-16 | 2023-12-01 | Ikena Oncology Inc | MEK inhibitors and their use |
| AU2022270072A1 (en) | 2021-05-03 | 2023-11-02 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| PH12023500023A1 (en) | 2021-05-07 | 2024-03-11 | Kymera Therapeutics Inc | Cdk2 degraders and uses thereof |
| WO2023288197A1 (en) * | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
| EP4376844A1 (en) | 2021-07-30 | 2024-06-05 | Eli Lilly and Company | Treatment of hand eczema with baricitinib |
| EP4392422A1 (en) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| AR127505A1 (es) | 2021-10-29 | 2024-01-31 | Kymera Therapeutics Inc | Degradadores irak-4 y síntesis de los mismos |
| CN114373808B (zh) * | 2021-11-26 | 2023-11-10 | 江苏科来材料科技有限公司 | 一种高效晶硅电池 |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN114149437A (zh) * | 2021-12-24 | 2022-03-08 | 安徽大学 | 一种吡咯并嘧啶五元氮杂环衍生物及其制备方法和用途 |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| US12084430B2 (en) | 2022-03-17 | 2024-09-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2023194842A1 (en) | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Substituted tricyclic compounds and their use in rheumatoid arthritis |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| IL316768A (en) | 2022-05-25 | 2025-01-01 | Ikena Oncology Inc | MEK inhibitors and their uses |
| CN117384163A (zh) * | 2022-07-05 | 2024-01-12 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
| IL318575A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF |
| EP4565569A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| CN115181103B (zh) * | 2022-08-16 | 2023-11-07 | 上海博悦生物科技有限公司 | 一种巴瑞替尼的制备方法 |
| AR131141A1 (es) | 2022-11-22 | 2025-02-19 | Pic Therapeutics Inc | Inhibidores de eif4e y usos de los mismos |
| CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
| WO2024193496A1 (zh) * | 2023-03-17 | 2024-09-26 | 北京普祺医药科技股份有限公司 | 吡咯并嘧啶化合物或其可药用盐的制备方法 |
| CN116444529B (zh) * | 2023-06-16 | 2023-12-05 | 药康众拓(江苏)医药科技有限公司 | 一种氘代氮杂环丁烷类jak抑制剂及其用途 |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| BR9609613A (pt) | 1995-07-05 | 1999-05-25 | Du Pont | Composto composição fungicida e método de controle de doenças de plantas |
| NZ312665A (en) | 1995-07-06 | 1999-08-30 | Novartis Ag | Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these |
| TR200100189T2 (tr) | 1998-06-04 | 2001-05-21 | Abbott Laboratories | Hücre yapışması engelleyici iltihaplanmaya karşı bileşikler |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| DE69916833T2 (de) | 1998-06-19 | 2005-04-14 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-verbindungen |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| SK287188B6 (sk) | 1999-12-10 | 2010-02-08 | Pfizer Products Inc. | Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom |
| DZ3377A1 (fr) * | 1999-12-24 | 2001-07-05 | Aventis Pharma Ltd | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| CA2413313C (en) * | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| ES2257410T3 (es) | 2000-06-26 | 2006-08-01 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores. |
| CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| DE60216115T2 (de) | 2001-08-01 | 2007-05-31 | Merck & Co., Inc. | BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE |
| BR0212760A (pt) | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| BRPI0213739B8 (pt) | 2001-10-30 | 2021-05-25 | Dana Farber Cancer Inst Inc | derivados de estaurosporina como inibidores da atividade de receptores flt3 de tirosina cinase |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US20040019066A1 (en) * | 2002-05-06 | 2004-01-29 | Institut Pasteur | Methionine salvage pathway in bacillus |
| BR0309844A (pt) * | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| JPWO2004007472A1 (ja) * | 2002-07-10 | 2005-11-17 | 小野薬品工業株式会社 | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| ATE371656T1 (de) | 2002-11-04 | 2007-09-15 | Vertex Pharma | Heteroaryl-pyrimidinderivate als jak-inhibitoren |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| JP2006509000A (ja) | 2002-11-26 | 2006-03-16 | ファイザー・プロダクツ・インク | 移植片拒絶反応の処置の方法 |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| BRPI0416909A (pt) | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | método de tratamento de aterosclerose |
| EP1734967A2 (en) | 2003-12-17 | 2006-12-27 | Pfizer Products Incorporated | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
| US20050165029A1 (en) * | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| PT1730146E (pt) | 2004-03-30 | 2011-07-11 | Vertex Pharma | Azaindoles úteis como inibidores de jak e outras proteínas quinases |
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
| JP2007536310A (ja) | 2004-05-03 | 2007-12-13 | ノバルティス アクチエンゲゼルシャフト | Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤 |
| JP2007537296A (ja) | 2004-05-14 | 2007-12-20 | アボット・ラボラトリーズ | 治療薬としてのキナーゼ阻害薬 |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| WO2006001463A1 (ja) * | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| EP1885352A2 (en) | 2004-11-24 | 2008-02-13 | Novartis AG | Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| JP5227032B2 (ja) | 2005-02-03 | 2013-07-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピリミジン |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2609126A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| EP1926735A1 (en) * | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| LT2426129T (lt) * | 2005-12-13 | 2017-02-10 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
| WO2007076423A2 (en) | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
| US7767816B2 (en) | 2006-01-17 | 2010-08-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of janus kinases |
| WO2007117494A1 (en) * | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| TW200805992A (en) * | 2006-07-04 | 2008-01-16 | Benq Corp | Method and apparatus for barring short message |
| US8513270B2 (en) * | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
| PL2173752T5 (pl) * | 2007-06-13 | 2022-12-05 | Incyte Holdings Corporation | Sole (r)-3-(4-(7h-pirolo(2,3-d)pirymidyn-4-ylo)-1h-pirazol-1-ilo)-3-cyklopentylopropanonitrylu inhibitora kinazy janusowej |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
-
2009
- 2009-03-10 EA EA201071057A patent/EA017218B1/ru active Protection Beyond IP Right Term
- 2009-03-10 CA CA2718271A patent/CA2718271C/en active Active
- 2009-03-10 SG SG2013044821A patent/SG191660A1/en unknown
- 2009-03-10 DK DK09718650.6T patent/DK2288610T3/en active
- 2009-03-10 LT LTEP09718650.6T patent/LT2288610T/lt unknown
- 2009-03-10 PT PT97186506T patent/PT2288610T/pt unknown
- 2009-03-10 BR BRPI0909040A patent/BRPI0909040B8/pt active IP Right Grant
- 2009-03-10 PL PL09718650T patent/PL2288610T3/pl unknown
- 2009-03-10 CN CN200980116857.7A patent/CN102026999B/zh active Active
- 2009-03-10 EP EP09718650.6A patent/EP2288610B8/en active Active
- 2009-03-10 ES ES09718650.6T patent/ES2602577T3/es active Active
- 2009-03-10 TW TW098107750A patent/TWI444382B/zh active
- 2009-03-10 UA UAA201010917A patent/UA101493C2/ru unknown
- 2009-03-10 RS RS20160911A patent/RS55263B1/sr unknown
- 2009-03-10 HR HRP20161390TT patent/HRP20161390T1/hr unknown
- 2009-03-10 KR KR1020127020848A patent/KR20120108042A/ko not_active Ceased
- 2009-03-10 AU AU2009223640A patent/AU2009223640B2/en active Active
- 2009-03-10 MX MX2010010012A patent/MX2010010012A/es active IP Right Grant
- 2009-03-10 HU HUE09718650A patent/HUE029767T2/en unknown
- 2009-03-10 NZ NZ587928A patent/NZ587928A/xx unknown
- 2009-03-10 KR KR1020107020309A patent/KR101240882B1/ko active Active
- 2009-03-10 US US12/401,348 patent/US8158616B2/en active Active
- 2009-03-10 SI SI200931524A patent/SI2288610T1/sl unknown
- 2009-03-10 JP JP2010550808A patent/JP5275371B2/ja active Active
- 2009-03-10 MY MYPI2010004226A patent/MY165582A/en unknown
- 2009-03-10 WO PCT/US2009/036635 patent/WO2009114512A1/en active Application Filing
- 2009-03-10 CN CN201410017280.7A patent/CN103788098A/zh active Pending
- 2009-03-11 PA PA20098819201A patent/PA8819201A1/es unknown
- 2009-03-11 AR ARP090100869A patent/AR070828A1/es active IP Right Grant
- 2009-03-11 CL CL2009000576A patent/CL2009000576A1/es unknown
- 2009-03-11 PE PE2009000355A patent/PE20091712A1/es active IP Right Grant
- 2009-03-11 PE PE2013000889A patent/PE20140099A1/es not_active Application Discontinuation
- 2009-03-11 UY UY31705A patent/UY31705A1/es active IP Right Grant
-
2010
- 2010-08-23 ZA ZA2010/06000A patent/ZA201006000B/en unknown
- 2010-09-03 HN HN2010001761A patent/HN2010001761A/es unknown
- 2010-09-06 IL IL208023A patent/IL208023A/en active Protection Beyond IP Right Term
- 2010-09-08 DO DO2010000270A patent/DOP2010000270A/es unknown
- 2010-09-08 TN TNP2010000415A patent/TN2010000415A1/fr unknown
- 2010-09-10 SV SV2010003662A patent/SV2010003662A/es unknown
- 2010-09-10 EC EC2010010475A patent/ECSP10010475A/es unknown
- 2010-09-24 CO CO10118687A patent/CO6290658A2/es active IP Right Grant
- 2010-10-11 MA MA33236A patent/MA32219B1/fr unknown
-
2011
- 2011-12-09 US US13/315,750 patent/US8420629B2/en active Active
-
2013
- 2013-02-11 DO DO2013000036A patent/DOP2013000036A/es unknown
- 2013-03-13 JP JP2013050687A patent/JP2013155179A/ja not_active Withdrawn
- 2013-03-29 US US13/853,475 patent/US20130225556A1/en not_active Abandoned
-
2016
- 2016-10-31 CY CY20161101100T patent/CY1118176T1/el unknown
-
2017
- 2017-07-07 NL NL300886C patent/NL300886I2/nl unknown
- 2017-07-10 CY CY2017024C patent/CY2017024I2/el unknown
- 2017-07-11 LU LU00027C patent/LUC00027I2/fr unknown
- 2017-07-11 NO NO2017033C patent/NO2017033I1/no unknown
- 2017-07-14 LT LTPA2017023C patent/LTC2288610I2/lt unknown
- 2017-07-18 HU HUS1700031C patent/HUS1700031I1/hu unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B25G | Requested change of headquarter approved |
Owner name: INCYTE HOLDINGS CORPORATION (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: INCYTE HOLDINGS CORPORATION (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |